In today’s data-driven healthcare landscape, life sciences companies are increasingly interested in obtaining insights beyond traditional randomized clinical trials. Real world evidence (RWE) has emerged as a valuable approach for generating insights using real patient data collected during routine clinical practice. RWE offers opportunities to better understand patient outcomes, safety, and effectiveness outside of strict clinical trial settings.
What is Real World Evidence?
Real world evidence refers to clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of real world data. Real world data encompasses data related to patient health status and healthcare collected from a variety of sources, including electronic health records, claims and billing activities, product and disease registries, patient-powered mobile device apps, and other digital sources. When analyzed using rigorous study designs and methodologies, real world data can provide insights to complement traditional research methods.
Applications Of Pharmaceutical And Life Sciences Real World Evidence
Real world evidence is being leveraged across the pharmaceutical and life sciences for a variety of applications:
Comparative Effectiveness Research: RWE allows comparisons between real world effectiveness of existing medical treatments or interventions to evaluate their relative safety, efficacy, and clinical outcomes. Such research helps inform treatment guidelines and payor coverage decisions.
Post Surveillance: Pharmaceutical companies utilize RWE to monitor drug performance, effectiveness, and safety over the full patient population and duration of treatment after regulatory approval and launch. This supports identification of rare or long-term adverse events not detected in clinical trials.
Healthcare Decision Making: Payors, providers, policymakers, and life sciences organizations are using RWE to evaluate cost-effectiveness of treatment options and guide formulary coverage lists, clinical pathways, and quality improvement programs. Real world insights complement randomized control trial results to inform complex healthcare resource allocation decisions.
Clinical Trial Design: Insights from RWE can aid pharmaceutical companies in refining or redirecting clinical trial programs based on understanding of current treatment patterns, response variability across patient populations, and optimal endpoint selection to reduce development time and costs while ensuring trial validity and relevance.
Medical Product Development: Real world datasets are increasingly used early in the drug development process for target validation, natural history studies, and identification of biomarkers to streamline clinical research and development of new medical therapies.
Challenges In Real World Evidence Generation
While RWE offers many promising applications, generating high quality evidence from real world data also faces challenges:
Data Quality and Bias: Real world data sources were not primarily designed for research purposes and often have inconsistencies, missing values, and other quality issues that require cleaning and validation prior to analysis. There is also inherent selection bias as patients opt-in to data capture.
Lack of Randomization: The non-randomized nature of real world data precludes controlling for all confounding variables as in clinical trials. Rigorous methods like propensity score matching must be applied to isolate treatment effects from underlying patient characteristics.
Interoperability Issues: Heterogeneity across data systems poses technical challenges in merging diverse data sources and ensuring consistent definitions and terminologies that allow aggregating real world evidence at scale.
Privacy and Regulatory Concerns: Sharing identifiable patient information while adhering to strict privacy regulations requires robust data security protocols and oversight from research ethics boards.
Analytical Complexity: Analyzing real world data often involves sophisticated longitudinal study designs, advanced statistical modeling, and machine learning to glean meaningful insights despite inherent “noisiness” compared to clinical trials. Technical skills remain limited in some organizations.
Placebo Effects: Placebo-controlled trials remain important for certain research questions as real world evidence may not fully account for placebo effects seen in clinical practice.
Future Outlook
While Pharmaceutical and Life Sciences Real World Evidence generation still faces hurdles, maximizing its potential offers tremendous promise to transform healthcare decision making and advance patient-centered medical innovation. As real world data sources grow exponentially in volume and completeness through digitization across settings of care, methodologies will continue maturing to realize robust insights. Already, RWE is augmenting traditional evidence sources used by life sciences and complementing the clinical development process. With appropriate analysis and governance, real world data can power discoveries empowering providers, researchers, and patients alike.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Priya Pandey
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. LinkedIn Profile